107 related articles for article (PubMed ID: 9143913)
1. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors.
Wilson CA; Ng TH; Miller AE
Hum Gene Ther; 1997 May; 8(7):869-74. PubMed ID: 9143913
[TBL] [Abstract][Full Text] [Related]
2. Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors.
Chen J; Reeves L; Cornetta K
Hum Gene Ther; 2001 Jan; 12(1):61-70. PubMed ID: 11177543
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus.
Martineau D; Klump WM; McCormack JE; DePolo NJ; Kamantigue E; Petrowski M; Hanlon J; Jolly DJ; Mento SJ; Sajjadi N
Hum Gene Ther; 1997 Jul; 8(10):1231-41. PubMed ID: 9215740
[TBL] [Abstract][Full Text] [Related]
4. Detection of ecotropic replication-competent retroviruses: comparison of s(+)/l(-) and marker rescue assays.
Reeves L; Duffy L; Koop S; Fyffe J; Cornetta K
Hum Gene Ther; 2002 Sep; 13(14):1783-90. PubMed ID: 12396630
[TBL] [Abstract][Full Text] [Related]
5. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays.
Printz M; Reynolds J; Mento SJ; Jolly D; Kowal K; Sajjadi N
Gene Ther; 1995 Mar; 2(2):143-50. PubMed ID: 7719931
[TBL] [Abstract][Full Text] [Related]
6. Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
Lamers CH; Willemsen RA; van Elzakker PM; Gratama JW; Debets R
J Immunother; 2009 Apr; 32(3):272-9. PubMed ID: 19242373
[TBL] [Abstract][Full Text] [Related]
7. An improved method for detection of replication-competent retrovirus in retrovirus vector products.
Uchida E; Sato K; Iwata A; Ishii-Watabe A; Mizuguchi H; Hikata M; Murata M; Yamaguchi T; Hayakawa T
Biologicals; 2004 Sep; 32(3):139-46. PubMed ID: 15536044
[TBL] [Abstract][Full Text] [Related]
8. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research.
Chen J; Reeves L; Sanburn N; Croop J; Williams DA; Cornetta K
Virology; 2001 Mar; 282(1):186-97. PubMed ID: 11259201
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences.
Otto E; Jones-Trower A; Vanin EF; Stambaugh K; Mueller SN; Anderson WF; McGarrity GJ
Hum Gene Ther; 1994 May; 5(5):567-75. PubMed ID: 8054374
[TBL] [Abstract][Full Text] [Related]
10. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.
Cornetta K; Yao J; House K; Duffy L; Adusumilli PS; Beyer R; Booth C; Brenner M; Curran K; Grilley B; Heslop H; Hinrichs CS; Kaplan RN; Kiem HP; Kochenderfer J; Kohn DB; Mailankody S; Norberg SM; O'Cearbhaill RE; Pappas J; Park J; Ramos C; Ribas A; Rivière I; Rosenberg SA; Sauter C; Shah NN; Slovin SF; Thrasher A; Williams DA; Lin TY
Mol Ther; 2023 Mar; 31(3):801-809. PubMed ID: 36518078
[TBL] [Abstract][Full Text] [Related]
11. Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line.
Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV
Virology; 2000 Jan; 266(1):170-9. PubMed ID: 10612671
[TBL] [Abstract][Full Text] [Related]
12. Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious.
Ebeling SB; Simonetti ER; Borst HP; Blok A; Schelen AM; Braakman E; Ederveen J; Hagenbeek A
Gene Ther; 2003 Oct; 10(21):1800-6. PubMed ID: 12960969
[TBL] [Abstract][Full Text] [Related]
13. Detection of replication competent retrovirus and lentivirus.
Sastry L; Cornetta K
Methods Mol Biol; 2009; 506():243-63. PubMed ID: 19110631
[TBL] [Abstract][Full Text] [Related]
14. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells.
Long Z; Li LP; Grooms T; Lockey C; Nader K; Mychkovsky I; Mueller S; Burimski I; Ryan P; Kikuchi G; Ennist D; Marcus S; Otto E; McGarrity G
Hum Gene Ther; 1998 May; 9(8):1165-72. PubMed ID: 9625255
[TBL] [Abstract][Full Text] [Related]
15. Endogenous murine leukemia virus DNA sequences in murine cell lines: implications for gene therapy safety testing by PCR.
Allan DS; De Koven A; Wild A; Kamel-Reid S; Dubé ID
Leuk Lymphoma; 1996 Oct; 23(3-4):375-81. PubMed ID: 9031120
[TBL] [Abstract][Full Text] [Related]
16. Safety considerations in vector development.
Kappes JC; Wu X
Somat Cell Mol Genet; 2001 Nov; 26(1-6):147-58. PubMed ID: 12465466
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of replication-competent retrovirus.
Forestell SP; Dando JS; Böhnlein E; Rigg RJ
J Virol Methods; 1996 Jul; 60(2):171-8. PubMed ID: 8844623
[TBL] [Abstract][Full Text] [Related]
18. [Bio-safety testing for retroviral vector as gene therapy delivery system].
Zhu M; Dai Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Mar; 13(1):48-50. PubMed ID: 12759953
[TBL] [Abstract][Full Text] [Related]
19. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
20. Infection of human cells with murine amphotropic replication-competent retroviruses.
Cornetta K; Nguyen N; Morgan RA; Muenchau DD; Hartley JW; Blaese RM; Anderson WF
Hum Gene Ther; 1993 Oct; 4(5):579-88. PubMed ID: 8280796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
